Astrana Health, Inc.
ASTH
$30.89
$0.070.23%
Weiss Ratings | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Fair | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | C | |||
Rating Factors | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Good | |||
Solvency Index | Excellent | |||
Total Return Index | Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.83 | |||
Price History | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 5.81% | |||
30-Day Total Return | -13.67% | |||
60-Day Total Return | -7.71% | |||
90-Day Total Return | -34.22% | |||
Year to Date Total Return | -4.07% | |||
1-Year Total Return | -22.13% | |||
2-Year Total Return | -21.16% | |||
3-Year Total Return | -37.86% | |||
5-Year Total Return | 181.59% | |||
52-Week High % Change | -51.12% | |||
52-Week Low % Change | 33.61% | |||
Price | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $63.20 | |||
52-Week Low Price | $23.12 | |||
52-Week Low Price (Date) | Feb 28, 2025 | |||
52-Week High Price (Date) | Oct 16, 2024 | |||
Valuation | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 1.55B | |||
Enterprise Value | 1.53B | |||
Price/Earnings (TTM) | 34.71 | |||
Earnings Per Share (TTM) | 0.89 | |||
Earnings Per Share Growth | -30.91% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 0.70 | |||
Price/Book (Q) | 2.08 | |||
Enterprise Value/Revenue (TTM) | 0.75 | |||
Price | $30.89 | |||
Enterprise Value/EBITDA (TTM) | 13.05 | |||
Enterprise Value/EBIT | 17.13 | |||
Market Cap Category | Small Cap | |||
Dividends and Shares | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 46.34M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | 9.35% | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 626 282 0288 | |||
Address | 1668 S. Garfield Avenue Alhambra, CA 91801 | |||
Website | www.astranahealth.com | |||
Country | United States | |||
Year Founded | 1994 | |||
Profitability | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | 4.39% | |||
Profit Margin | 2.12% | |||
Management Effectiveness | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | 4.88% | |||
Return on Equity | 10.80% | |||
Income Statement | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 13.98M | |||
Total Revenue (TTM) | 2.03B | |||
Revenue Per Share | $43.90 | |||
Gross Profit (TTM) | 271.39M | |||
EBITDA (TTM) | 117.28M | |||
EBIT (TTM) | 89.35M | |||
Net Income (TTM) | 43.15M | |||
Net Income Avl. to Common (TTM) | 43.15M | |||
Total Revenue Growth (Q YOY) | 88.43% | |||
Earnings Growth (Q YOY) | -8,173.40% | |||
EPS Diluted (TTM) | 0.89 | |||
EPS Diluted Growth (Q YOY) | -158.09% | |||
Balance Sheet | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 290.85M | |||
Cash Per Share (Q) | $6.28 | |||
Total Current Assets (Q) | 638.50M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 514.17M | |||
Current Ratio (Q) | 1.746 | |||
Book Value Per Share (Q) | $14.87 | |||
Total Assets (Q) | 1.35B | |||
Total Current Liabilities (Q) | 365.61M | |||
Total Debt (Q) | 471.84M | |||
Total Liabilities (Q) | 840.73M | |||
Total Common Equity (Q) | 712.72M | |||
Cash Flow | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -192.40M | |||
Cash from Financing (TTM) | 135.15M | |||
Net Change in Cash (TTM) | -5.05M | |||
Levered Free Cash Flow (TTM) | 65.38M | |||
Cash from Operations (TTM) | 52.20M | |||